ParcelBio
Elevated mRNA for transformative medicines.
ParcelBio is a business in healthcare based in San Francisco, CA, USA.
Profile
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
ParcelBio is positioned in healthcare, a segment that rewards a clear, focused offering.
San Francisco, CA, USA is where the company is located.
Directory data places it at the Winter 2024 stage.
Its team size is recorded as 6 employees.
Directory analysis
ParcelBio is a San Francisco‑based biotech focused on developing a novel class of mRNA medicines that aim to deliver higher potency and longer durability than current mRNA therapies. The company’s proprietary APEXm™ platform incorporates unique RNA domains to boost protein expression and extend therapeutic activity, targeting autoimmune diseases, oncology, and encoded protein therapeutics.
Positioning: ParcelBio positions itself in the competitive mRNA therapeutics space, differentiating through its APEXm™ platform that seeks to enhance efficacy and durability. Its early-stage focus on autoimmune and oncology indications places it among emerging players aiming to address unmet medical needs.
Note: ParcelBio is a small, early‑stage biotech with a proprietary mRNA platform targeting autoimmune and cancer therapies.
Auto-generated directory analysis from public data · updated 10 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 6 |
| Stage | Winter 2024 |
Website: parcelbio.com
Browse related
Create a free account